Beatriz García Díaz, Stefan Gross, Irmgard Assfalg-Machleidt, Dietmar Pfeiler, Nicole Gollmitzer, Dusica Gabrijelcic-Geiger, Milton T. Stubbs, Hans Fritz, Ennes A. Auerswald, Werner Machleidt
Cystatins as Calpain Inhibitors: Engineered Chicken Cystatin- and Stefin B-Kininogen Domain 2 Hybrids Support a Cystatin-Like Mode of Interaction with the Catalytic Subunit of µ-Calpain
Within the cystatin superfamily, only kininogen domain 2 (KD2) is able
to inhibit µ- and m-calpain. In an attempt to elucidate the structural
requirements of cystatins for calpain inhibition, we constructed
recombinant hybrids of human stefin B (an intracellular family 1
cystatin) with KD2 and ?L110 deletion mutants of chicken cystatin-KD2
hybrids. Substitution of the N-terminal contact region of stefinB by
the corresponding KD2 sequence resulted in a calpain inhibitor of KI =
188 nM. Deletion of L110, which forms a ?-bulge in family 1 and 2
cystatins but is lacking in KD2, improved inhibition of µ-calpain 4- to
8-fold. All engineered cystatins were temporary inhibitors of calpain
due to slow substratelike cleavage of a single peptide bond
corresponding to Gly9-Ala10 in chicken cystatin. Biomolecular
interaction analysis revealed that, unlike calpastatin, the
cystatintype inhibitors do not bind to the calmodulinlike domain of
the small subunit of calpain, and their interaction with
the µ-calpain heterodimer is completely prevented by
a synthetic peptide comprising subdomain B of calpastatin domain 1. Based on these results we propose that (i) cystatin-type calpain inhibitors interact
with the active site of the catalytic domain of calpain
in a similar cystatinlike mode as with papain and (ii)
the potential for calpain inhibition is due to specific
subsites within the papain-binding regions of the
general cystatin fold.
Biological Chemistry, Walter de Gruyter
Print ISSN: 1431-6730
Volume: 382, 02/2001
Pages: 97 - 107
Show full article (external site)
Show all available items of this journal